

This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/advances

Half-sandwich complexes of ruthenium, osmium, rhodium and iridium with DLmethionine or S-methyl-L-cysteine: A solid state and solution equilibrium study

János Patalenszki^a, Linda Bíró^a, Attila Csaba Bényei^b, Tereza Radosova Muchova^{c,d}, Jana Kasparkova^c, Péter Buglyó^{a,*}

^a Department of Inorganic and Analytical Chemistry, University of Debrecen, H-4010 Debrecen, P.O.Box 21, Hungary.

^b Department of Physical Chemistry, University of Debrecen, H-4010 Debrecen P.O.Box 7, Hungary.

Abstract

 $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ binding strength of the thioether ligands DL-methionine (H₂met⁺) or S-methyl-L-cysteine (H₂mecys⁺) was studied with the combined use of pH-potentiometry, NMR and mass spectrometry in aqueous solution. Both ligands were found to form stable $[(\eta^{6}-p-\text{cym})\text{RuA}]^{+}$ complexes with [S, NH₂, COO⁻] coordination of the amino acids over a wide pH-range. A log β_{RuA} value of 17.2(2) was obtained from NMR titrations for the met system by a competition reaction with hydroxide ion. Comparison of the $[(\eta^6-p)$ cym)Ru(H₂O)₃]²⁺ binding strength of the [O,O,O] (citrate), [O,N,O] (isoserine) and [S,N,O] (met) donor sets at pH = 7.4 reveals the exclusive formation of [S,N,O] chelated metal complex. Synthesis and characterisation of $[(\eta^6-p-cym)Ru(L)]X$, $[(\eta^6-p-cym)Os(L)]Cl$ or $[(\eta^5-p-cym)Ru(L)]X$, $[(\eta^6-p-cym)Os(L)]Cl$ or $[(\eta^5-p-cym)Ru(L)]X$. Cp^*)M'(L)]Cl (L = mecys, DL-met, L-met; X = Cl, NO₃, CF₃SO₃; M' = Rh, Ir) complexes together with the molecular structures of the $[(\eta^6 - p - cym)Ru(mecys)]NO_3$ (10) and $[(\eta^6 - p - cym)Ru(mecys)]NO_3$ (10) cvm)Ru(met)]NO₃ (11) obtained by X-ray diffraction method are reported. Both tridentate ligands form chiral-at-metal complexes in which the configuration of the metal centre is determined by the ligands containing stereogenic centre (α C) too. Diffraction data indicate that 10 contains the $R_{Ru}R_{\alpha C}S_{S}$ stereoisomer while 11 consists of the $R_{Ru}S_{\alpha C}R_{S}$ and $S_{Ru}R_{\alpha C}S_{S}$ enantiomers in the lattice. Owing to the labile configuration of the thioether sulfurs epimerisation in both systems was detected and the ratio of the diastereomers was estimated. 11 together with $[(\eta^6-p-cym)Ru(L-met)]Cl$ (3), $[(\eta^5-Cp^*)Rh(DL-met)]Cl$ (7) and $[(\eta^5-Lp^*)Rh(DL-met)]Cl$ (7) and Cp*)Ir(DL-met)]Cl (9) were tested for their in vitro cytotoxicity using human-derived ovarian cancer lines (A2780) and showed no anti-proliferative activity in the concentration range (0-50 µM) studied.

^c Department of Biophysics, Faculty of Science, Palacky University, 17. Listopadu 12, 77146 Olomouc, Czech Republic.

^d Department of Biophysics, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacky University, Slechtitelu 11, 78371 Olomouc, Czech Republic.

Introduction

Biotransformation reactions of half-sandwich type platinum metal complexes with potential antiproliferative activity¹⁻⁵ are of great importance for a deeper understanding of their *in vivo* activity and to develop even more selective and effective compounds as potential anticancer drugs. During the biotransformation processes the half-sandwich complexes with potential antiproliferative activity, depending upon kinetic characteristics and thermodynamic stability, may undergo aquation and subsequent ligand substitution with the involvement of large (albumin, transferrin, immunoglobulin etc.) or low molecular weight components (eg. carbonate, lactate, citrate, glutamate, cysteine, glutathione etc.) of the serum.^{1,2}

To understand the most important factors influencing the stability of these complexes a systematic study has been started in our laboratories. Regarding the donor atom preference of the half-sandwich type metal core comparison of the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ binding strengths of various bidentate and tridentate ligands with different type of donor atoms were explored in aqueous solution. It was found that low basicity (O,O) chelators (oxalate, cyclobutane-dicarboxylate) are effective metal ion binders under acidic conditions only.⁶ Lactate with the mixed [COO⁻, O⁻] binding set cannot hinder the metal ion from hydrolysis at pH = 7.4 either. Complementing, however, the donors with a further carboxylate, the low molecular mass (l.m.m.) serum components, citrate or malate, were found to bind $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ very efficiently even in the basic pH-range in the form of monomeric complexes with different protonation degree.^{7,8} The role of the alcoholate group in effective binding was proven with the comparison of tricarballate ligand as it was found that for the [COO⁻, COO⁻, COO⁻] binding set the metal ion has only very little affinity at neutral pH.⁷

Replacement of one carboxylate in citrate or malate by an amino group results in an effective $[O, NH_2, COO]$ chelating set in serine or isoserine. It was also demonstrated that among the chelates that can be formed with these amino acid ligands the one incorporating five-membered [COO, O] binding site in isoserine is more stable in terms of ruthenium binding than the six-membered one with serine.⁹

Substitution of the hard alcoholate by a soft sulfur donor may result in a more favourable environment for these type metal ions. Although the thiolate containing cysteine or penicillamine systems¹⁰⁻¹⁵ are more explored especially in the solid state for the thioethers methionine (H_2met^+) or S-methyl-cysteine (H_2mecys^+) (with one CH₂ unit shorter side chain, see Scheme 1) less information is available on the interaction with half-sandwich type

platinum metal ions. In an earlier study synthesis and characterization of $[(\eta^5-Cp^*)Ru^{II}(met)]$ (Cp^{*} = pentamethylcyclopentadienyl) with tridentate coordination of the ligand was reported¹⁶ while X-ray structure of the analogous $[(\eta^5-Cp^*)Ir^{III}(mecys)]CF_3SO_3 \cdot 0.5H_2O$ was shown to feature identical (S,N,O) coordinating ligand with R_{Ir} and S_S configurations in the molecule.¹⁷ Adding a strongly coordinating monodentate ligand to the system in $[(\eta^5-Cp)Ru^{II}(PPh_3)(met)]$ (N,O) coordination of the amino acid was suggested according to the IR data.¹⁸ Based on the formation of stable complexes sequence-selective detection of Metcontaining oligopeptides was also demonstrated with the use of the $[(\eta^5-Cp^*)Rh^{III}$ type building block as chemosensor.¹⁹ In a recent work a combined NMR and MS study on the interaction of $[(\eta^6-p-cym)RuCl_2]_2$ and methionine in aqueous solution indicated the formation of a (S,N,O) coordinated major complex 48 h being necessary to reach equilibrium in solution. Samples obtained by the dilution of the DMSO solution of $[(p-cym)RuCl_2]_2$ and 6-10 fold excess of met with water were found to exhibit strong cytotoxicity against human ovarian cancer cell lines (A2780 and A2780CisR) with IC₅₀ values of 0.54(7) and 3.53(39) μ M, respectively.²⁰

Upon coordination of a non-symmetrical chelating²¹ or three different monodentate ligands in these half-sandwich complexes the metal ion becomes a stereogenic centre and in the case of met or mecys further stereogenic centres (α C and thioether S) are also present resulting in the formation of diastereomers.^{22,23} Dissolution of this type of solid complexes, depending upon kinetic or thermodynamic control of the reactions under a given set of experimental conditions, the configuration of the metal and the sulfur (but not the α C) atoms of the chiral-at-metal complexes can change and may therefore result in the interconversion of the diastereomers and makes also challenging the interpretation of the NMR data.²⁴

Since there appear to exist no detailed solution equilibrium results in the literature on the interaction between half-sandwich type $[(\eta^6-p\text{-}cym)M(H_2O)_3]^{2+}$ (*p*-cym = 1-isopropyl-4-methylbenzene; M = Ru, Os) or $[(\eta^5-Cp^*)M'(H_2O)_3]^{2+}$ (M' = Rh, Ir) metal ions and thioether-containing amino acids (Scheme 1) we have undertaken a combined study with the aid of pH-potentiometry, NMR, ESI-MS methods to explore the most likely solution structures and to estimate the stability constants of the complexes formed with $[(\eta^6-p\text{-}cym)Ru(H_2O)_3]^{2+}$ that was selected as model. We have also synthesized and characterized the appropriate complexes in the solid state and studied their transformation reactions and stereochemical features upon dissolving the solids. This paper summarizes the obtained results.

Experimental Section

Materials and methods

RuCl₃·xH₂O, α -terpinene, OsO₄, $[(\eta^5-Cp^*)RhCl_2]_2$, $[(\eta^5-Cp^*)IrCl_2]_2$, AgNO₃, AgCF₃SO₃, Smethyl-L-(-)-cysteine, L-(+)-methionine, DL-methionine were commercial products (Merck, Acros Organics, W.C. Heraeus, Strem Chemicals, Reanal) and used as received. CH₃OH, acetone, CH₂Cl₂, C₂H₅OH, CH₃CN, diisopropyl ether and NaOMe used for the preparation of solid complexes were produced by Sharlau, WVR and Sigma Aldrich. Methanol was dried and distilled according to standard methods.²⁵ $[(\eta^6-p-cym)RuCl_2]_2$ or $[(\eta^6-p-cym)OsCl_2]_2$ were synthesized and purified according to a literature procedures.^{26,27} Aqueous solution of $[(\eta^6-p$ cym)Ru(acetone)₃](NO₃)₂ or $[(\eta^6-p-cym)Ru(acetone)_3](CF_3SO_3)_2$ were obtained from $[(\eta^6-p-cym)Ru(acetone)_3](NO_3)_2$ cym)RuCl₂]₂ by the removal of chloride ion using equivalent amounts of appropriate silver salts. ¹H, ¹³C NMR, COSY and HSQC spectra were recorded on a Bruker Avance 360 or 400 NMR instrument at room temperature in D₂O or CD₃OD and referenced to 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt (TSP) or to resonances of the solvents. The low temperature spectra (10 °C and 0 °C) were registered on a Bruker Avance 400 or a Bruker Avance DRX-500 spectrometer in D₂O. ESI-TOF MS analysis of the prepared complexes in the positive mode was carried out on a Bruker micrOTOF₀ instrument. The measurements were performed in water at 0.3 mM metal ion concentration. Temperature of drying gas (N₂) was 180°C. The pressure of the nebulizating gas (N₂) was 0.3 bar. The flow rate was 3 μ L/min. The spectra were accumulated and recorded by a digitalizer at a sampling rate of 2 GHz. DataAnalysis (version 3.4) was used for the calculations. IR spectra were recorded on an Perkin Elmer FTIR Paragon 1000 PC instrument. Elemental analyses were conducted on Elementar Vario MICRO CUBE instrument at the Department of Organic Chemistry, University of Debrecen, Hungary.

Crystal structure analysis

Diffraction intensity data collection was carried out at 293(2) K on a Bruker-Nonius MACH3 diffractometer equipped with a point detector using graphite-monochromated Mo-*K* α radiation ($\lambda = 0.71073$ Å). The structure was solved by SIR-92 program²⁸ and refined by full-matrix least-squares method on F^2 , with all non-hydrogen atoms refined with anisotropic

thermal parameters using the SHELXL-97 package.²⁹ Publication material was prepared with the WINGX- suite.³⁰ Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were treated with a mixture of independent and constrained refinement. C-H hydrogen atoms were refined using a riding model. Crystallographic and experimental details are summarized in Table 1. The remaining peaks at the difference electron density maps are located close to the ruthenium atoms. All the crystallographic data for **10** and **11** are deposited in the Cambridge Crystallographic Data Centre under CCDC 1025973 and 1025974.

Synthesis of complexes

General procedure for the preparation of $[(\eta^6 - p - cym)M(L)]Cl$ or $[(\eta^5 - Cp^*)M'(L)]Cl$ (M = Ru, Os; M' = Rh, Ir; L = mecys, DL-met, L-met) complexes

To a mixture of the corresponding ligand (2 equiv.) and $[(\eta^6-p-cym)MCl_2]_2$ or $[(\eta^5-Cp^*))M^2Cl_2]_2$ (1 equiv.), in a 25 mL Schlenk tube was added 5-10 ml abs. methanol under N₂ at room temperature and stirred for 0.5 h, protected from light. NaOMe (2 equiv.) was added to the solution and further stirred for 2-5 h. The reaction mixture was than evaporated at reduced pressure and extracted with CH₂Cl₂. By slow addition of diisopropyl ether at -20 °C to the extracts resulted in the formation of pale yellow to orange microcrystalline products. The solids were filtered, washed with a small amount of diethyl ether and dried under vacuum at ambient temperature. If no solid was formed the solvent was removed under vacuum and CH₃CN or C₂H₅OH was used as solvent. Diisopropyl ether was added to the solutions and the mixtures were kept at -20 °C to obtain solids. The products were worked up as before.

[(η⁶-*p***-cym)Ru(mecys)]Cl·0.3H₂O (1).** S-methyl-L-(–)-cysteine (54.1 mg, 0.40 mmol), [(η⁶*p*-cym)RuCl₂]₂ (122.6 mg, 0.20 mmol), NaOMe (21.1 mg, 0.39 mmol). Yield: 66.0 mg, 40.2% (yellow solid). Found: C, 40.15; H, 5.27; N, 3.35; S, 7.85. Calc. for C₁₄H₂₂ClNO₂RuS·0.3H₂O (M_r 410.32): C, 40.98; H, 5.55; N, 3.41; S, 7.81. IR (KBr): v_{max}/cm⁻¹ = 3433 br and 3087 s (NH); 1651 vs (CO). δ_H (400 MHz, D₂O, T = 25 °C, TSP): 1.27 (d, ³J = 7.5 Hz, 3H, cym-CH(CH₃)₂), 1.29 (d, ³J = 7.5 Hz, 3H, cym-CH(CH₃)₂), 2.22 (s, 3H, cym-CH₃), 2.39 (s, 3H, S-CH₃), 2.40 (d, ²J = 14.6 Hz, 1H, β-CH₂), 2.79 (h, 1H, cym-CH(CH₃)₂), 2.80 (dd, ²J = 14.6 Hz, ³J = 4.4 Hz, 1H, β-CH₂), 3.84 (d, ³J = 4.1 Hz, 1H, α-CH), 5.74 (d, ³J = 6.0 Hz, 1H, cym-H), 5.89 (d, ³J = 6.1 Hz, 1H, cym-H), 5.92 (d, ³J = 6.2 Hz, 1H, cym-H), 6.08 (d, ³J = 6.0 Hz, 1H, cym-H). Minor isomer: 1.32 (d, ³J = 6.8 Hz, 3H, cym-CH(CH₃)₂), 2.27 (s, 3H, cym-CH₃); 2.85 (s, 3H, S-CH₃); 3.03 (d, ²J = 13.3 Hz, 1H, β -CH₂), 3.76 (d, ³J = 4.2 Hz, 1H, α -CH), 5.43 (d, ³J = 5.9 Hz, 1H, cym-H). δ_{C} (100 MHz, D₂O, TSP): 20.3 (cym-CH₃), 24.2 (cym-CH(CH₃)₂), 24.3 (cym-CH(CH₃)₂), 24.8 (S-CH₃), 30.1 (β -CH₂), 33.6 (cym-CH(CH₃)₂), 61.2 (α -CH), 84.9 (cym-CH), 85.2 (cym-CH), 86.0 (cym-CH), 86.5 (cym-CH), 102.3 (cym-C), 109.0 (cym-C), 182.9 (mecys-COO⁻). Minor isomer: 20.6 (cym-CH₃), 29.1 (S-CH₃), 37.7 (β -CH₂), 59.7 (α -CH), 81.2 (cym-CH), 85.1 (cym-CH), 89.0 (cym-CH). MS (ESI-TOF): m/z (%) = 370.033 (100) [ML]⁺ (simulated: 370.041).

[(η⁶-*p*-cym)Ru(DL-met)]Cl·0.5H₂O (2). DL-methionine (60.2 mg, 0.40 mmol), [(η⁶-*p*cym)RuCl₂]₂ (123.1 mg, 0.20 mmol), NaOMe (21.3 mg, 0.39 mmol). Yield: 26.0 mg, 15.2% (yellow solid). Found: C, 41.75; H, 5.85; N, 3.34; S, 7.54. Calc. for C₁₅H₂₄ClNO₂RuS·0.5H₂O (M_r 427.95): C, 42.10; H, 5.89; N, 3.27; S 7.49. IR (KBr): v_{max}/cm⁻¹ = 3433 br and 3051 s (NH); 1644 vs (CO). δ_H (360 MHz, D₂O, T = 25 °C, TSP): 1.28 (d, ³J = 6.8 Hz, 6H, cym-CH(CH₃)₂), 1.80 (br, 1H, β-CH₂), 2.16 (br, 3H, cym-CH₃ + 1H, β-CH₂ + 1H, γ-CH₂), 2.72 (m, 3H, S-CH₃ + 1H, cym-CH(CH₃)₂), 3.05 (m, 1H, γ-CH₂), 3.61 (br, 1H, α-CH), 5.73-5.94 (m, 4H, cym-H). Minor isomer: 2.21 (s, 3H, S-CH₃), 5.46 (br, 1H, cym-H). MS (ESI-TOF): m/z (%) = 384.052 (100) [ML]⁺ (simulated: 384.057).

[(η⁶-*p*-cym)Ru(L-met)]Cl·0.4H₂O (3). L-(+)-methionine (60.0 mg, 0.40 mmol), [(η⁶-*p*-cym)RuCl₂]₂ (122.8 mg, 0.20 mmol), NaOMe (21.7 mg, 0.40 mmol). Yield: 87.7 mg, 51.4% (pale orange solid). Found: C, 42.31; H, 5.92; N, 3.31; S, 7.60. Calc. for C₁₅H₂₄ClNO₂RuS·0.4H₂O (M_r 426.15): C, 42.28; H, 5.87; N, 3.29; S 7.52. IR (KBr) ν_{max} /cm⁻¹: 3465 br, 3114 s and 3031 s (NH); 1660 vs (CO). $\delta_{\rm H}$ (500 MHz, D₂O, T = 25 °C, TSP): 1.28 (d, ³J = 6.8 Hz, 6H, cym-CH(*CH*₃)₂), 1.80 (br, 1H, β-CH₂), 2.17 (br, 3H, cym-CH₃ + 1H, β-CH₂ + 1H, γ-CH₂), 2.71 (m, 3H, S-CH₃ + 1H, cym-CH(CH₃)₂), 3.05 (m, 1H, γ-CH₂), 3.62 (br, 1H, α-CH), 5.72-5.93 (m, 4H, cym-H). Minor isomer: 2.21 (s, 3H, S-CH₃), 5.46 (br, 1H, cym-H). $\delta_{\rm H}$ (500 MHz, D₂O, T = 0 °C, TSP): 1.28 (m, 6H, cym-CH(CH₃)₂), 1.79 (m, 1H, β-CH₂), 2.16 (m, 3H, cym-CH₃ + 1H, β-CH₂ + 1H, γ-CH₂), 3.60 (br, 1H, α-CH), 5.71 (d, ²J = 6.1 Hz, 1H, cym-H), 5.79 (d, ²J = 6.1 Hz, 1H, cym-H), 5.89 (d, ²J = 6.0 Hz, 1H, cym-H), 5.95 (d, ²J = 6.1 Hz, 1H, cym-H). Minor isomer: 2.19 (s, 3H, cym-CH₃), 2.69 (s, 3H, S-CH₃), 2.84 (m, 1H, cym-CH(CH₃)₂), 3.71 (br, 1H, α-CH), 5.44 (d, ²J = 5.8 Hz, 1H, cym-H), 5.77 (d, ²J = 5.7 Hz, 1H, cym-H). MS (ESI-TOF): m/z (%) = 384.053 (100) [ML]⁺ (simulated: 384.057).

RSC Advances Accepted Manuscript

 $[(\eta^{6}-p-cym)Os(mecys)]Cl$ (4). S-methyl-L-(-)-cysteine (54.7 mg, 0.40 mmol), $[(\eta^{6}-p-cym)Os(mecys)]Cl$ (4). cym)OsCl₂l₂ (159.7 mg, 0.20 mmol), NaOMe (21.9 mg, 0.41 mmol). Yield: 117.2 mg, 59.3% (pale yellow solid). Found: C, 33.64; H, 4.63; N, 2.85; S, 6.46. Calc. for C₁₄H₂₂ClNO₂OsS $(M_r 494.08)$: C, 34.03; H, 4.49; N, 2.83; S, 6.49. IR (KBr) v_{max}/cm^{-1} : 3465 br and 3083 s (NH); 1659 vs (CO). $\delta_{\rm H}$ (360 MHz, D₂O, T = 25 °C, TSP): 1.25 (d, ³J = 6.7 Hz, 3H, cym-CH(CH₃)₂), 1.27 (d, ${}^{3}J = 6.7$ Hz, 3H, cym-CH(CH₃)₂), 2.29 (s, 3H, cym-CH₃), 2.39 (d, ${}^{2}J =$ 14.9 Hz, 1H, β -CH₂), 2.43 (s, 3H, S-CH₃), 2.70 (h, ³J = 6.9 Hz, 1H, cym-CH(CH₃)₂) 2.87 (dd, 2 J = 14.6 Hz, 3 J = 4.2 Hz, 1H, β -CH₂), 4.05 (d, 3 J = 3.8 Hz, 1H, α -CH), 5.94 (d, 3 J = 5.6 Hz, 1H, cym-H), 6.05 (d, ${}^{3}J = 6.1$ Hz, 1H, cym-H), 6.13 (d, ${}^{3}J = 5.6$ Hz, 1H, cym-H), 6.27 (d, {}^{3}J = 5.6 Hz, 1H, cym-H), 6.27 (d, {}^{3}J = 5.6 Hz, 1H, cym-H), 6.27 (d, {}^{3}J = 5.6 Hz 5.5 Hz, 1H, cym-H). Minor isomer: 2.35 (s, 3H, cym-CH₃); 2.53 (dd, ${}^{2}J = 13.1$ Hz, ${}^{3}J = 4.5$ Hz, 1H, β-CH₂), 2.93 (s, 3H, S-CH₃); 2.97 (d, ${}^{2}J = 13.4$ Hz, 1H, β-CH₂), 3.90 (d, ${}^{3}J = 3.9$ Hz, 1H, α -CH), 5.66 (d, ³J = 5.6 Hz, 1H, cym-H). $\delta_{\rm H}$ (360 MHz, CD₃OD, T = 25 °C, solvent residual): 1.30 (d, ${}^{3}J = 6.7$ Hz, 3H, cym-CH(CH₃)₂), 1.32 (d, ${}^{3}J = 6.6$ Hz, 3H, cym-CH(CH₃)₂), 2.31 (s, 3H, cym-CH₃), 2.40 (d, ${}^{2}J = 14.3$ Hz, 1H, β -CH₂), 2.48 (s, 3H, S-CH₃), 2.71 (h, ${}^{3}J =$ 6.9 Hz, 1H, cym-CH(CH₃)₂) 2.85 (dd, ${}^{2}J = 14.4$ Hz, ${}^{3}J = 4.1$ Hz, 1H, β -CH₂), 3.92 (d, ${}^{3}J = 3.5$ Hz, 1H, α-CH), 5.93 (d, ${}^{3}J = 5.5$ Hz, 1H, cvm-H), 6.02 (d, ${}^{3}J = 6.1$ Hz, 1H, cvm-H), 6.13 (d, ${}^{3}J$ = 5.5 Hz, 1H, cym-H), 6.25 (d, ${}^{3}J$ = 5.6 Hz, 1H, cym-H). Minor isomer: 2.38 (s, 3H, cym-CH₃), 2.56 (dd, ${}^{2}J = 13.0 \text{ Hz}$, ${}^{3}J = 4.3 \text{ Hz}$, 1H, β -CH₂), 2.91 (d, ${}^{2}J = 13.4 \text{ Hz}$, 1H, β -CH₂), 2.98 (s, 3H, S-CH₃), 3.78 (d, ${}^{3}J = 3.8$ Hz, 1H, α -CH), 5.62 (d, ${}^{3}J = 5.5$ Hz, 1H, cym-H), 6.29 (d, ${}^{3}J$ = 5.4 Hz, 1H, cym-H). MS (ESI-TOF): m/z (%) = 460.095 (100) [ML]⁺ (simulated: 460.098).

[(η⁶-*p*-cym)Os(DL-met)]Cl·0.4H₂O (5). DL-methionine (60.46 mg, 0.41 mmol), [(η⁶-*p*-cym)OsCl₂]₂ (159.1 mg, 0.20 mmol), NaOMe (21.6 mg, 0.40 mmol). Yield: 43.1 mg, 20.9% (yellow solid). Found: C, 34.51; H, 4.88; N, 2.71; S, 6.31. Calc. for C₁₅H₂₄ClNO₂OsS·0.4H₂O (M_r 515.31): C, 34.96; H, 4.85; N, 2.72; S 6.22. IR (KBr) v_{max}/cm⁻¹: 3434 br and 3053 s (NH); 1650 vs (CO). δ_H (500 MHz, D₂O, T = 25 °C, TSP): 1.27 (d, ³J = 6.9 Hz, 6H, cym-CH(CH₃)₂), 2.03 (br, 1H, β-CH₂), 2.23 (s, 3H, cym-CH₃), 2.45 (m, 1H, β-CH₂ + 1H, γ-CH₂), 2.67 (br, 1H, cym-CH(CH₃)₂), 2.81 (s, 1H, S-CH₃), 3.15 (br, 1H, γ-CH₂), 3.78 (br, 1H, α-CH), 5.91 (m, 2H, cym-H). δ_H (500 MHz, D₂O, T = 0 °C, TSP): 1.27 (m, 6H, cym-CH(CH₃)₂), 2.02 (m, 1H, β-CH₂), 2.21 (s, 3H, cym-CH₃) 2,43 (m, 1H, β-CH₂ + 1H, γ-CH₂), 2.65 (h, ²J = 6.7 Hz, 1H, cym-CH(CH₃)₂), 2.82 (s, 3H S-CH₃) 3.18 (m, 1H, γ-CH₂), 3.76 (br,

1H, α -CH), 5.89 (d, ³J = 6.1 Hz, 1H, cym-H), 5.90 (d, ³J = 5.9 Hz, 1H, cym-H), 6.11 (m, 2H, cym-H). Minor isomer: 2.24 (s, 3H, cym-CH₃), 2.32 (m, 1H, β -CH₂), 2.55 (m, 1H, β -CH₂), 2.75 (h, ²J = 6.8 Hz, 1H, cym-CH(CH₃)₂), 3.91 (br, 1H, α -CH), 5.72 (d, ³J = 6.0 Hz, 1H, cym-H), 6.15 (d, ³J = 5.1 Hz, 1H, cym-H), 6.17 (d, ³J = 5.6 Hz, 1H, cym-H). MS (ESI-TOF): m/z (%) = 474.111 (100) [ML]⁺ (simulated: 474.114).

[(η⁵-Cp*)Rh(mecys)]Cl (6). S-methyl-L-(–)-cysteine (35.6 mg, 0.26 mmol), [(η⁵-Cp*)RhCl₂]₂ (80.0 mg, 0.13 mmol), NaOMe (14.1 mg, 0.26 mmol). Yield: 4.2 mg, 4.0% (hygroscopic orange solid). $\delta_{\rm H}$ (400 MHz, D₂O, T = 25 °C, TSP): 1.83 (s, 15H, Cp*-CH₃), 2.38 (s, 3H, S-CH₃), 2.64 (d, ²J = 14.7 Hz, 1H, β-CH₂), 3.01 (dd, ²J = 14.6 Hz, ³J = 3.6 Hz, 1H, β-CH₂), 3.96 (br, 1H, α-CH). Minor: 1.75 (s, 15H, Cp*-CH₃). $\delta_{\rm H}$ (400 MHz, D₂O, T = 0 °C, TSP): 1.83 (s, 15H, Cp*-CH₃), 2.38 (s, 3H, S-CH₃), 2.38 (s, 3H, S-CH₃), 2.65 (d, ²J = 14.8 Hz, 1H, β-CH₂), 2.99 (dd, ²J = 14.7 Hz, ³J = 4.0 Hz, 1H, β-CH₂), 3.96 (br, 1H, α-CH). Minor isomer: 1.76 (s, 15H, Cp*-CH₃), 2.72 (s, 3H, S-CH₃), 3.28 (d, ²J = 13.4 Hz, 1H, β-CH₂), 3.86 (br, 1H, α-CH).

[(η⁵-Cp*)Rh(DL-met)]Cl·0.3H₂O (7). DL-methionine (19.7 mg, 0.13 mmol), [(η⁵-Cp*)RhCl₂]₂ (40.2 mg, 0.065 mmol), NaOMe (14.3 mg, 0.26 mmol). Yield: 29.1 mg, 52.4% (orange solid). Found: C, 41.73; H, 6.08; N, 3.26; S, 7.53. Calc. for C₁₅H₂₅ClNO₂RhS·0.3H₂O (M_r 427.19): C, 42.17; H, 6.04; N, 3.28; S 7.60. IR (KBr) v_{max}/cm⁻¹: 3473 s, 3414 s, 3116 s, 3053 s (NH); 1645 vs (CO). $\delta_{\rm H}$ (400 MHz, D₂O, T = 25 °C, TSP): 1.72 (s, 15H, Cp*-CH₃), 2.11 (br, 1H, β-CH₂), 2.27 (m, 1H, β-CH₂), 2.40 (br, 1H, γ-CH₂), 2.58 (s, 3H, S-CH₃), 3.10 (br, 1H, γ-CH₂), 3.86 (s, 1H, α-CH). $\delta_{\rm H}$ (400 MHz, D₂O, T = 0 °C, TSP): 1.72 (br, 15H, Cp*-CH₃), 1.98-2,44 (m, 2H, β-CH₂ + 1H, γ-CH₂), 2.62 (s, 3H, S-CH₃), 3.07 (m, 1H, γ-CH₂), 3.88 (br, 1H, α-CH). Minor isomer: 2.52 (s, 3H, S-CH₃), 3.20 (m, 1H, γ-CH₂), 3.81 (br, 1H, α-CH). MS (ESI-TOF): m/z (%) = 380.060 (100) [ML]⁺ (simulated: 380.066).

[(η⁵-Cp*)Ir(mecys)]Cl·0.4CH₃CN·0.5H₂O (8). S-methyl-L-(–)-cysteine (27.1 mg, 0.20 mmol), [(η⁵-Cp*)IrCl₂]₂ (79.5 mg, 0.10 mmol), NaOMe (21.6 mg, 0.40 mmol). Yield: 28.9 mg, 27.7% (yellow solid). Found: C, 33.53; H, 4.91; N, 3.85; S, 6.06. Calc. for C₁₄H₂₃ClIrNO₂S·0.4CH₃CN·0.5H₂O (M_r 522.50): C, 34.02; H, 4.86; N, 3.75; S, 6.14. IR (KBr) v_{max}/cm⁻¹: 3424 br, 3221 br and 2984 s (NH); 1666 vs (CO). δ_H (360 MHz, D₂O, T = 25 °C, TSP): 1.85 (s, 15H, Cp*-CH₃), 2.42 (s, 3H, S-CH₃), 2.67 (d, ²J = 14.7 Hz, 1H, β-CH₂), 3.03 (dd, ²J = 14.7 Hz, ³J = 4.2 Hz, 1H, β-CH₂), 4.31 (d, ³J = 3.8 Hz, 1H, α-CH). Minor

isomer: 1.83 (s, 15H, Cp*-CH₃), 2.79 (s, 3H, S-CH₃), 3.25 (d, ${}^{2}J$ = 13.2 Hz, 1H, β -CH₂), 4.11 (d, ${}^{3}J$ = 3.8 Hz, 1H, α -CH). MS (ESI-TOF): m/z (%) = 426.104 (100) [ML]⁺ (simulated: 426.107).

[(η⁵-Cp*)Ir(DL-met)]Cl·0.5H₂O (9). DL-methionine (30.1 mg, 0.20 mmol), $[(η^5-Cp*)IrCl_2]_2$ (79.7 mg, 0.10 mmol), NaOMe (21.8 mg, 0.40 mmol). Yield: 52.7 mg, 50.7% (yellow solid). Found: C, 34.48; H, 5.09; N, 2.70; S, 6.15. Calc. for C₁₅H₂₅CIIrNO₂S·0.5H₂O (M_r 520.11): C, 34.64; H, 5.04; N, 2.69; S 6.17. IR (KBr) v_{max}/cm^{-1} : 3483 s, 3421 s, 3095 br and 3033 s (NH); 1666 vs (CO). δ_H (400 MHz, D₂O, T = 25 °C, TSP): 1.70 (s, 15H, Cp*-CH₃), 2.22-2.61 (m, 1H, γ -CH₂ + 2H, β -CH₂), 2.74 (s, 3H, S-CH₃), 3.27 (m, 1H, γ -CH₂), 4.17 (m, 1H, α -CH). Minor isomer: 1.73 (s, 15H, Cp*-CH₃), 2.53 (s, 3H, S-CH₃), 4.10 (m, 1H, α -CH). δ_H (400 MHz, D₂O, T = 0 °C, TSP): 1.71 (s, 15H, Cp*-CH₃), 2.21-2.60 (m, 1H, γ -CH₂ + 2H, β -CH₂), 2.75 (s, 3H, S-CH₃), 3.28 (m, 1H, γ -CH₂), 4.16 (m, 1H, α -CH). Minor isomer: 1.73 (s, 15H, Cp*-CH₃), 2.54 (s, 3H, S-CH₃), 4.09 (m, 1H, α -CH). MS (ESI-TOF): m/z (%) = 476.116 (100) [ML]⁺ (simulated: 476.123).

General procedure for the preparation of $[(\eta^6 - p - cym)Ru(L)]X$ ($L = mecys, DL-met; X = NO_3, CF_3SO_3$)

AgNO₃ or AgCF₃SO₃ (4 equiv.) was added to a solution of $[(\eta^6-p-cym)RuCl_2]_2$ (1 equiv.) in dry acetone (8-10 mL) giving an orange-red solution and immediate precipitation of AgCl. The mixture was protected from light, stirred at r.t. for 60 min, and filtered to remove AgCl. The solution was evaporated, and the orange-red thick oil was dried in vacuo. The oil was dissolved in 5-10 ml abs. methanol in a Schlenk tube and the corresponding ligand (2 equiv.) and NaOMe (2 equiv.) were added and stirred for 2-3 h in the dark. The reaction mixture was evaporated at reduced pressure and dissolved in 96 % ethanol. Orange microcrystalline products were formed after addition of diisopropyl ether at -20 °C. The solids were filtered, washed with a small amount of diethyl ether and dried under vacuum at ambient temperature. For $[(\eta^6-p-cym)Ru(mecys)]NO_3$ (10) and $[(\eta^6-p-cym)Ru(DL-met)]NO_3$ (11) the products were directly suitable for X-ray analysis.

[(η⁶-*p***-cym)Ru(mecys)]NO₃ (10).** [(η⁶-*p*-cym)RuCl₂]₂ (122.7 mg, 0.20 mmol), AgNO₃ (135.0 mg, 0.79 mmol), (S-methyl-L-(–)-cysteine (53.6 mg, 0.40 mmol), NaOMe (21.4 mg, 0.40 mmol). Yield: 76.4 mg, 88.5% (orange solid). Found: C, 38.55; H, 5.23; N, 6.55; S, 7.58.

RSC Advances Accepted Manuscript

Calc. for C₁₄H₂₂N₂O₅RuS (M_r 431.47): C, 38.97; H, 5.14; N, 6.49; S, 7.43. IR (KBr) v_{max}/cm⁻¹: 3442 br and 3062 s (NH); 1656 vs (CO); 1384 vs and 1302 vs (NO). δ_H (400 MHz, D₂O, T = 25 °C, TSP): 1.26 (d, ³J = 7.6 Hz, 3H, cym-CH(CH₃)₂), 1.28 (d, ³J = 7.5 Hz, 3H, cym-CH(CH₃)₂), 2.21 (s, 3H, cym-CH₃), 2.38 (s, 3H, S-CH₃), 2.40 (d, ²J = 14.5 Hz, 1H, β -CH₂), 2.78 (h, 1H, cym-CH(CH₃)₂), 2.78 (dd, ²J = 14.5 Hz, ³J = 2.9 Hz, 1H, β -CH₂), 3.84 (d, ³J = 3.6 Hz, 1H, α -CH), 5.73 (d, ³J = 5.9 Hz, 1H, cym-H), 5.88 (d, ³J = 5.9 Hz, 1H, cym-H), 5.91 (d, ³J = 6.2 Hz, 1H, cym-H), 6.07 (d, ³J = 5.9 Hz, 1H, cym-H). Minor isomer: 1.32 (d, ³J = 6.5 Hz, 3H, cym-CH(CH₃)₂), 2.26 (s, 3H, cym-CH₃); 2.83 (s, 3H, S-CH₃); 3.04 (d, ²J = 12.6 Hz, 1H, β -CH₂), 3.76 (d, ³J = 3.2 Hz, 1H, α -CH), 5.42 (d, ³J = 5.3 Hz, 1H, cym-H). MS (ESI-TOF): m/z (%) 370.033 (100) [ML]⁺ (simulated: 370.041).

 $[(\eta^{6}-p-cym)Ru(DL-met)]NO_{3}\cdot 0.1EtOH (11). [(\eta^{6}-p-cym)RuCl_{2}]_{2} (122.5 mg, 0.20 mmol),$ AgNO₃ (135,3 mg, 0,80 mmol), DL-methionine (59.7 mg, 0.40 mmol), NaOMe (21.4 mg, 0.40 mmol). Yield: 146.8 mg, 81.5% (orange solid). Found: C, 40.75; H, 5.65; N, 6.14; S, 7.14. Calc. for C₁₅H₂₄N₂O₅RuS·0.1EtOH (*M*_r 450.10): C, 40.56; H, 5.51; N, 6.22; S 7.12. IR (KBr) v_{max}/cm⁻¹: 3435 br, 3151 br and 3080 br (NH); 1655 vs (CO); 1383 vs, 1341 vs and 1322 vs (NO). $\delta_{\rm H}$ (500 MHz, D₂O, T = 25 °C, TSP): 1.28 (d, ³J = 6.8 Hz, 6H, cym-CH(CH₃)₂), 1.81 (br, 1H, β -CH₂), 2.17 (br, 3H, cym-CH₃ + 1H, β -CH₂ + 1H, γ -CH₂), 2.72 (m, 3H, S-CH₃ + 1H, cym-CH(CH₃)₂), 3.05 (m, 1H, γ -CH₂), 3.62 (br, 1H, α -CH), 5.72-5.93 (m, 4H, cym-H). Minor isomer: 2.21 (s, 3H, S-CH₃), 5.46 (br, 1H, cym-H). δ_H (500 MHz, D₂O, T = 0 °C, TSP): 1.28 (m, 6H, cym-CH(CH₃)₂), 1.79 (m, 1H, β -CH₂), 2.17 (m, 3H, cym-CH₃ + 1H, β -CH₂ + 1H, γ -CH₂), 2.72 (m, 3H, S-CH₃ + 1H, cym-CH(CH₃)₂), 3.07 (m, 1H, γ -CH₂), 3.59 (br, 1H, α -CH), 5.71 (d, ²J = 6.0 Hz, 1H, cym-H), 5.79 (d, ²J = 6.2 Hz, 1H, cym-H), 5.88 (d, ${}^{2}J = 6.1$ Hz, 1H, cym-H), 5.95 (d, ${}^{2}J = 6.1$ Hz, 1H, cym-H). Minor isomer: 2.19 (s, 3H, cym-CH₃), 2.69 (s, 3H, S-CH₃), 2.83 (m, 1H, cym-CH(CH₃)₂), 3.70 (br, 1H, α-CH), 5.44 (d, 2 J = 5.9 Hz, 1H, cym-H), 5.77 (d, 2 J = 5.6 Hz, 1H, cym-H). δ_{C} (100 MHz, D₂O, T = 0 °C, TSP): 19.8 (cym-CH₃), 24.0 (cym-CH(CH₃)₂), 24.3 (cym-CH(CH₃)₂), 29.0 (β-CH₂), 29.4 (S-CH₃), 32.9 (γ-CH₂), 33.4 (cym-CH(CH₃)₂), 56.5 (α-CH), 85.7 (cym-CH), 87.6 (cym-CH), 88.1 (cym-CH), 102.6 (cym-C), 107.5 (cym-C), 186.3 (met-COO⁻). Minor isomer: 20.1 (cym-CH₃), 24.4 (cym-CH(CH₃)₂), 24.5 (cym-CH(CH₃)₂), 25.0 (S-CH₃), 26.8 (β-CH₂), 30.2 (γ-CH₂), 57.2 (α-CH), 82.1 (cym-CH), 87.0 (cym-CH), 89.5 (cym-CH), 104.0 (cym-C), 108.4 (cym-*C*), 185.6 (met-*C*OO⁻). MS (ESI-TOF): m/z (%) 384.049 (100) [ML]⁺ (simulated: 384.057).

RSC Advances Accepted Manuscript

 $[(\eta^{6}-p-cym)Ru(mecys)]CF_{3}SO_{3}$ (12). $[(\eta^{6}-p-cym)RuCl_{2}]_{2}$ (62.0 mg, 0.10 mmol), AgCF_{3}SO_{3} (102.8 mg, 0.40 mmol), (S-methyl-L-(-)-cysteine (27.2 mg, 0.20 mmol), NaOMe (21.9 mg, 0.41 mmol). Yield: 39.4 mg, 38.0% (yellow solid). Found: C, 34.12; H, 4.20; N, 2.61; S, 12.41. Calc. for C₁₅H₂₂F₃NO₅RuS₂ (*M*_r 518.53): C, 34.74; H, 4.28; N, 2.70; S, 12.37. IR (KBr) v_{max}/cm⁻¹: 3462 br, 3246 s, 3207 s and 3088 s (NH); 1666 vs (CO); 1256 s, 1226 s and 1165 s (CF); 1031 s and 638 s (SO). $\delta_{\rm H}$ (360 MHz, D₂O, T = 25 °C, TSP): 1.26 (d, ³J = 7.2 Hz, 3H, cym-CH(CH₃)₂), 1.28 (d, ${}^{3}J = 7.2$ Hz, 3H, cym-CH(CH₃)₂), 2.20 (s, 3H, cym-CH₃), 2.38 (s, 3H, S-CH₃), 2.40 (d, ${}^{2}J = 14.5$ Hz, 1H, β -CH₂), 2.77 (h, 1H, cym-CH(CH₃)₂) 2.77 (dd, 2 J = 14.4 Hz, 3 J = 4.8 Hz, 1H, β -CH₂), 3.83 (d, 3 J = 3.8 Hz, 1H, α -CH), 5.73 (d, 3 J = 6.0 Hz, 1H, cym-*H*), 5.88 (d, ${}^{3}J = 6.1$ Hz, 1H, cym-*H*), 5.91 (d, ${}^{3}J = 6.5$ Hz, 1H, cym-*H*), 6.07 (d, {}^{3}J = 6.5 Hz, 1H, cym-*H*), 6.07 (d, {} 5.9 Hz, 1H, cym-H). Minor isomer: 1.32 (d, ${}^{3}J = 6.6$ Hz, 3H, cym-CH(CH₃)₂), 2.26 (s, 3H, cym-CH₃); 2.83 (s, 3H, S-CH₃); 3.04 (d, ${}^{2}J = 13.2$ Hz, 1H, β -CH₂), 3.75 (d, ${}^{3}J = 3.6$ Hz, 1H, α -CH), 5.41 (d, ³J = 6.1 Hz, 1H, cym-H). $\delta_{\rm H}$ (400 MHz, CD₃OD, solvent residual): 1.30 (d, ³J = 7.0 Hz, 3H, cym-CH(CH₃)₂), 1.33 (d, ${}^{3}J$ = 7.0 Hz, 3H, cym-CH(CH₃)₂), 2.22 (s, 3H, cym-CH₃), 2.40 (d, ${}^{2}J = 14.4$ Hz, 1H, β -CH₂), 2.43 (s, 3H, S-CH₃), 2.74 (d, ${}^{2}J = 14.5$ Hz, ${}^{3}J = 4.0$ Hz, 1H, β-CH₂), 2.79 (h, ${}^{3}J = 6.9$ Hz, 1H, cym-CH(CH₃)₂), 3.72 (d, ${}^{3}J = 3.7$ Hz, 1H, α-CH), 5.74 (d, ${}^{3}J = 6.0$ Hz, 1H, cym-H), 5.86 (d, ${}^{3}J = 6.0$ Hz, 1H, cym-H), 5.91 (d, ${}^{3}J = 5.8$ Hz, 1H, cym-*H*), 6.07 (d, ³J = 6.0 Hz, 1H, cym-*H*). Minor isomer: 2.27 (s, 3H, cym-CH₃); 2.86 (s, 3H, S-CH₃); 2.99 (d, ${}^{2}J = 13.1$ Hz, 1H, β -CH₂), 3.64 (d, ${}^{3}J = 3.8$ Hz, 1H, α -CH), 5.37 (d, ${}^{3}J = 5.8$ Hz, 1H, cym-H), 5.95 (d, ${}^{3}J = 6.0$ Hz, 1H, cym-H), 6.12 (d, ${}^{3}J = 5.8$ Hz, 1H, cym-H). MS (ESI-TOF): m/z (%) = 370.033 (100) [ML]⁺ (simulated: 370.041).

[(η⁶-*p***-cym)Ru(DL-met)]CF₃SO₃ (13).** [(η⁶-*p*-cym)RuCl₂]₂ (61.2 mg, 0.10 mmol), AgCF₃SO₃ (101.5 mg, 0.39 mmol), DL-methionine (30.2 mg, 0.20 mmol), NaOMe (21.3 mg, 0.39 mmol). Yield: 66.38 mg, 62.3% (orange solid). Found: C, 35.94; H, 4.63; N, 2.68; S, 12.18. Calc. for C₁₆H₂₄F₃NO₅RuS₂ (M_r 532.56): C, 36.08; H, 4.54; N, 2.63; S 12.04. IR (KBr) v_{max}/cm⁻¹: 3446 br, 3222 s and 3072 s (NH); 1647 vs (CO); 1285 s, 1246 s and 1154 s (CF); 1028 s and 638 s (SO). $\delta_{\rm H}$ (360 MHz, D₂O, T = 25 °C, TSP): 1.28 (d, ³J = 6.8 Hz, 6H, cym-CH(*CH*₃)₂), 1.80 (br, 1H, γ-CH₂), 2.16 (br, 3H, cym-*CH*₃ + 1H, β-*CH*₂ + 1H, γ-*CH*₂), 2.71 (m, 3H, S-*CH*₃ + 1H, cym-*CH*(CH₃)₂), 3.04 (br, 1H, γ-*CH*₂), 3.61 (br, 1H, α-*CH*), 5.72-5.93 (m, 4H, cym-*H*). Minor isomer: 2.21 (s, 3H, S-*CH*₃), 5.46 (br, 1H, cym-*H*). MS (ESI-TOF): m/z (%) 384.049 (100) [ML]⁺ (simulated: 384.057).

Solution Studies

For solution studies doubly deionised and ultra-filtered water was obtained from a Milli-Q RG (Millipore) water purification system. pH-potentiometric measurements were carried out at an ionic strength of 0.20 M KNO₃ and at 25.0 ± 0.1 °C. Carbonate-free KOH solutions of known concentrations (*ca.* 0.2 M) were used as titrant. HNO₃ stock solutions were prepared from concentrated HNO₃ and their concentrations were determined by potentiometric titrations using the Gran's method.³¹ A Mettler Toledo T50 titrator with a Metrohm double junction electrode (type 6.0255.100) was used for the pH-metric measurements. The electrode system was calibrated according to Irving *et al.*,³² the pH-metric readings could therefore be converted into hydrogen ion concentration. The water ionization constant, pK_w , was 13.75 ± 0.01 under the conditions employed. Titrations were performed in the pH range 2.0 – 11.0. Initial volume of the samples was 15.00 mL. The metal ion concentrations were varied in the range 1.0 – 4.0 mM and 1:1, 1:2 and 2:1 metal to ligand ratios were titrated. The reproducibility of the equilibrium titration points included in the evaluation was within 0.005 pH unit. The samples were in all cases completely deoxygenated by bubbling purified argon for *ca.* 20 min prior the measurements.

¹H NMR titrations were carried out on a Bruker Avance 360 or 400 NMR instrument at room temperature in D₂O (99.8 %) or in H₂O (containing ~ 15 % D₂O in a sealed capillary) at c_{Ru} = 10-20 mM to register the pH dependence of the chemical shifts belonging to the hexahapto bonded *p*-cym, the pentahapto Cp* or the thioether ligands. Water saturation was achieved by low power irradiation during the relaxation delay. Chemical shifts are reported in ppm (δ_H) from 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt (TSP) as internal reference. pH was set up with NaOD or DNO₃ in D₂O and with KOH or HNO₃ in H₂O. Individual samples were equilibrated at least for two hours before measurements. pH* values (direct pH-meter readings in a D₂O solution of a pH-meter calibrated in H₂O according to Irving *et al.*)³² were converted to pH values measureable at an ionic strength of 0.20 M using the following equation: pH = 0.936pH* + 0.412.³³

For the ESI-MS analysis of the solutions the measurements were performed in water at 1.0 mM $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ concentration at different pH values and at 1:1 metal ion to ligand ratio.

Calculation of the stability constants $(\beta_{p,q,r} = [Ru_pA_qH_r]/[Ru]^p[A]^q[H]^r$; where "Ru" stands for $[(\eta^6-p-cym)Ru]^{2+}$ and "A" represents the mecys⁻ and met⁻ anions) of the complexes using the titration curves was attempted by the PSEQUAD or SUPERQUAD computer programs.^{34,35} During the calculations hydrolysis of $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ was taken into consideration and the following species was assumed: $[\{(\eta^6-p-cym)Ru\}_2(\mu^2-OH)_3]^+$ ($\log\beta_{2,0,-3} = -9.16$).³⁶ Ratios of the areas belonging to the corresponding NMR resonances of the free and complexed metal ion or ligand provided access to the stability constant of the $[(\eta^6-p-cym)Ru(met)]^+$ complex.

Cytotoxicity tests

Human ovarian carcinoma A2780 cells, kindly supplied by Professor B. Keppler, University of Vienna (Austria), were grown in RPMI 1640 medium (PAA; Pasching, Austria) supplemented with streptomycin (100 μ g L⁻¹), penicillin (100 U mL⁻¹) (both Sigma) and 10% heat inactivated fetal bovine serum (PAA; Pasching, Austria). The cells were cultured in a humidified incubator at 37 °C in a 5% CO₂ atmosphere and subcultured 2-3 times a week with an appropriate plating density.

Cytotoxic effect of the compounds 3, 7, 9 and 11 were evaluated by using assays based on the tetrazolium compound MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] metabolization and neutral red (NR) uptake. The adherent cells A2780 were plated out 16 h prior to testing in 96-well tissue culture plates at a density of 10^4 cells/well in 100 μ L of medium. The cells were treated for 72 h with the compounds at the final concentrations in the range of 0 to 50 µM in a final volume of 200 µL/well. Concentrations of the compounds in the medium during treatment were verified by flameless atomic absorption spectrometry. Thereafter, a viability of the cells was tested by both MTT and NR assays as described previously.³⁷ Briefly, after the treatment period, 10 µL of a freshly diluted MTT solution (2.5 mg mL⁻¹) was added to each well, and the plate was incubated at 37 $^{\circ}$ C in a humidified 5 % CO₂ atmosphere for 4 h. At the end of the incubation period, the medium was removed, and the formazan product was dissolved in 100 µL of dimethyl sulfoxide. Cell viability was evaluated by measurement of the absorbance at 570 nm, using an absorbance reader Synergy MX (Biotek, VT, USA); the reading values were converted to the percentage of the untreated control (percentage cell survival). Alternatively, after the treatment period, 20 µL of a 0.33% solution of neutral red in phosphate buffered saline (PBS) was added to each well with

adherent cells and the plate was incubated at 37 °C in a humidified 5 % CO₂ atmosphere for 2 h. Afterwards, the dye containing medium was carefully removed and the cells were quickly rinsed with PBS. The incorporated dye was then solubilized in 200 μ L of 1% acetic acid in 50% ethanol, allowed to stand for 10 min at room temperature and the absorbance was measured at λ =540 nm with absorbance reader Synergy MX (Biotek,VT, USA). The background absorbance of the plates at 690 nm was also measured and subtracted from 540 nm measurement. The reading values were converted to the percentage of the control (percentage cell survival). All experiments were repeated at least three times, each repetition made in triplicate.

Results and Discussion

To explore the solution behaviour of the half-sandwich type platinum metal ions with the title ligands, as a model, $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ was chosen and the interaction with DL-methionine (met) and S-methyl-L-cysteine (mecys) was studied in aqueous solution by the combined use of potentiometry, NMR and MS.

pH-potentiometric results

pH-potentiometric titrations assisted in checking the purity and exact concentration of the ligands and in redetermining their protonation constants. The estimated values appear in Table 2 and are in good agreement with those previously obtained under our experimental conditions.³⁸

Representative titration curves obtained for the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -containing samples with met (Fig. 1) indicate that the complex formation is already intensive at pH = 2.1. At 1:1 ratio the one equivalent of extra base consumption by pH = 6.0 clearly supports the exclusive formation of a 1:1 complex. Lack of any hydrolysis above pH = 9.0 is consistent with the tridentate coordination of the ligand. The exactly half equivalent of extra base consumption at 1:2 ratio indicates that here a 1:1 species is present too. From the 2:1 sample it is clear that the ligand is not capable of binding a second metal ion as the 1.5 equivalent of base consumption starting at pH ~ 3.5 is consistent with the hydrolysis of this excess of metal ion resulting in the formation of $[{(\eta^6-p-cym)Ru}_2(\mu^2-OH)_3]^+$.³⁶ Very similar titration curves and trends were

obtained for the mecys system too (see Fig. S1). Due to the high stability of the 1:1 complexes pH-potentiometry turned to be not suitable for the estimation of their stability constants.

NMR results

To identify the resonances in the NMR spectra of the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -ligand samples, spectra of the free ligands in the function of the pH were also registered. The assigned δ values together with the J values appear in Table 3. For both ligands the β -CH₂ hydrogens are magnetically non-equivalent as α -CH is a stereogenic centre. For mecys the multiplicity of these resonances is a distorted doublet of doublets (roof effect) as a consequence of geminal and vicinal spin-spin couplings while in the case of met a multiplet can be observed for β -CH₂ due to another vicinal couplings. For both ligands the multiplicity of the resonances of the hydrogens on α -C is also a doublet of doublets. On increasing the pH the δ values for the α -C hydrogens change the most while the methyl hydrogens being furthest from the deprotonation sites exhibit the smallest change.

NMR spectra registered in the range 0.99< pH <10.12 for the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -mecys system at 1:1 ratio (Fig. 2) indicate that the resonances of the *p*-cymene unit of the metal ion belong to a single major species. Neither signals of the uncomplexed $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ (2.24 ppm, cym-CH₃) nor that of $[{(\eta^6-p-cym)Ru}_2(\mu^2-OH)_3]^+$ (2.08 ppm, cym-CH₃)³⁶ can be detected in the range 1 < pH < 10 in accordance with the potentiometric results. Downfield shift of the α -CH (3.84 ppm) and S-CH₃ (2.39 ppm) protons of the ligand in the metal ion containing samples compared to those of the free deprotonated ligand (Table 3), furthermore, lack of pH-dependent shift of the resonances clearly supports the formation of [RuA]⁺ over a wide pH-range with tridentate coordination of mecys. Very similar trends were found with met too (see Fig. S2) with the only exception that the signals exhibit broadening. This is due to the frequency of some interconversion reactions in the complex (vide infra) being comparable to the frequency difference between the resonances. Identical stability trends and NMR behaviour were found for the $[(\eta^5-Cp^*)Ir(H_2O)_3]^{2+}$ containing systems too (not shown). NMR spectra registered in H₂O (see Experimental) for the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -met system in the range 12.5 < pH < 12.9 allowed the estimation of the stability constant of $[(n^6 - n^6)]$ p-cym)Ru(met)]⁺ by considering the ratio of the areas of the appropriate signals belonging to the complex and to the free ligand or $[{(\eta^6-p-cym)Ru}_2(\mu^2-OH)_3]^+$. As it is shown in Fig. 3 there is no indication for the formation of mixed hydroxido complexes as no new signals appear in the spectra in this pH-range beside those belonging to the uncomplexed ligand or $[{(\eta^6-p-cym)Ru}_2(\mu^2-OH)_3]^+$. The obtained stability constant appears in Table 2 while the calculated concentration distribution curves are shown in Fig. 4. As Fig. 4 reveals the concentrations of the $[(\eta^6-p-cym)Ru(met)]^+$ (**n**) and $[{(\eta^6-p-cym)Ru}_2(\mu^2-OH)_3]^+$ (\circ) obtained from the individual NMR experiments at various pH values are in agreement with the calculated concentrations.

Regarding the mecys system, slow colour change, decrease and disappearance of the signals of the analogous $[RuA]^+$ complex together with the appearance of new resonances in very basic solutions suggest irreversible processes making not possible the direct estimation of the stability constant of the $[(\eta^6-p-cym)Ru(mecys)]^+$ complex. Nevertheless, as Fig. 5 indicates, in a $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -met-mecys 1:1:1 system the ratio of the NMR resonances of the corresponding met and mecys complexes supports the slightly higher stability of $[(\eta^6-p-cym)Ru(met)]^+$ over the mecys complex and allows an estimation of $\log\beta = 16.4(4)$ for $[(\eta^6-p-cym)Ru(mecys)]^+$ using the $\log\beta = 17.2(2)$ of $[(\eta^6-p-cym)Ru(met)]^+$.

To compare the $[(\eta^6-p\text{-}cym)Ru(H_2O)_3]^{2+}$ binding capability of small tridentate bioligands with various [O,O,O] (citrate), [O,N,O] (isoserine) and [S,N,O] (methionine) donor atom sets, the distribution of the metal ion in a hypothetical $[(\eta^6-p\text{-}cym)Ru(H_2O)_3]^{2+}$ -citr--ise--met 1:1:1:1 system, as a function of pH, using the previously determined log β values^{7,9} and the data in Table 2, is calculated and shown in Fig. S3. The speciation indicates that both in the micromolar (Fig. S3a) and millimolar (Fig. S3b) concentration range of Ru(II) in the acidic and neutral pH range $[(\eta^6-p\text{-}cym)Ru(met)]^+$ is the single species present and the competition of isoserinate becomes significant only in the very basic pH range. Citrate with the alcoholate and carboxylate O donors is found to be the least effective binder among these small chelators, while met, even with the low basicity sulfur, has the highest affinity to the halfsandwich type metal ion.

ESI MS results

ESI-MS provided further information on the composition of the species present in aqueous solution. Spectra, registered in the range 1.1 < pH < 10.5, revealed the exclusive formation of $[RuA]^+$ in both systems with m/z values of 370.031 (mecys) and 384.052 (met). Neither any

form of the uncomplexed metal ion under acidic conditions nor $[{(\eta^6-p-cym)Ru}_2(\mu^2-OH)_3]^+(523.037)^{36}$ was detectable in the samples supporting thus the potentiometric and NMR results. As a representative example, MS spectrum of a $[(\eta^6-p-cym)Ru]^{2+}$ -met sample (pH = 10.8) together with the observed and expected spectra for $[(\eta^6-p-cym)Ru(met)]^+$ in the inlet are shown in Fig. 6.

Solid state studies

Reaction of $[(\eta^6-p-cym)MCl_2]_2$ (M = Ru, Os) or $[(\eta^5-Cp^*)M'Cl_2]_2$ (M' = Rh, Ir) with DL-met or L-mecys in MeOH afforded pale yellow to orange coloured solids in modest yield via the slow crystallization of the crude complexes from dichloromethane/isopropylether, acetonitrile/isopropylether or ethanol/isopropylether mixtures. Both elemental analysis and IR support the expected $[(\eta^6-p-cym)Ru(met/mecys)]X$ (X = Cl, NO₃, CF₃SO₃), $[(\eta^6-p$ $cym)Os(met/mecys)]Cl or <math>[(\eta^5-Cp^*)M'(met/mecys)]Cl$ general composition of the solids and the tridentate coordination of the ligands. In particular, v_{CO} values being in the range 1644-1666 cm⁻¹ (see Experimental) are consistent with the coordinating carboxylate.^{15,16,21}

Single crystals of **10** and **11** were grown by slow diffusion of isopropylether into an ethanolic solution of the complexes at 253 K. ORTEP views of $[(\eta^6-p-cym)Ru(mecys)]NO_3$ (10) and $[(\eta^6-p-cym)Ru(DL-met)]NO_3$ (11) are shown in Fig. 7 and 8 while key bond lengths and angles are summarized in Table 4. Both molecular structures contain tridentate ligands with [S, NH₂, COO⁻] coordination. In **10**, the configuration of the metal centre is also determined by the R absolute configuration of S-methyl-L-cysteine, therefore only the $R_{Ru}R_{\alpha C}$ stereoisomer is present. Upon coordination, the thioether-S also becomes a stereogenic centre in the molecule; in the lattice of 10 the stereoisomer with the $R_{Ru}R_{\alpha C}S_{S}$ absolute configuration found previously for $[(n^5$ only be detected. Identical behaviour was can Cp*)Ir(mecys)]CF₃SO₃·0.5H₂O too.¹⁷ Interestingly, the asymmetric unit of **10** contains two slightly different conformational isomers (Fig. S4).

For 11 with the racemic DL-methionine, two enantiomers, $R_{Ru}S_{\alpha C}R_S$ and $S_{Ru}R_{\alpha C}S_S$ in 1:1 ratio in the lattice, are detected (Fig. 8). Identical $R_MS_{\alpha C}R_S$ configuration was identified previously with L-met in $[(\eta^5-Cp^*)Co(L-met)]FeCl_4$.³⁹ Comparison of the structures 10 and 11 reveals that in both complexes the five-membered chelates have an envelope conformation with the N atom in the flap position. For 11 the six-membered chelate shows a distorted chair conformation with axial position of the thioether S donors. In both complexes the S-methyl

RSC Advances Accepted Manuscript

groups are parallel with the arene ring being closer to the NH₂ group in **11** and to the COO⁻ in **10**. The appropriate bond length and angle values are comparable with each other (Table 4) while the significantly larger N(1)-Ru(1)-S(1) angle in **11** can be rationalized by the one unit larger size of the (S,N) chelate. The solid state structures are stabilized by strong hydrogen bond networks with the participation of N-H protons and carboxylate or nitrate oxygen atoms as acceptors as well as by weak C-H····O hydrogen bonds.

Regardless of the counter ion, dissolving the solid complexes in various solvents practically identical NMR spectra could be obtained and these very much resembled to those of the corresponding metal ion-ligand systems previously studied in aqueous solution at different pH values. This, on the one hand, indicates that the tridentate coordination detected in the solid state is retained and, on the other hand, provides further support for the binding mode in aqueous solution, suggested previously. As representative examples, NMR spectra of $[(\eta^6-p$ cym)Ru(mecys)]NO₃ (10) in D₂O and $[(\eta^6-p-cym)Ru(mecys)]CF_3SO_3$ (12) in CD₃OD, respectively, as well as those of $[(\eta^6-p-cym)Os(mecys)]Cl$ (4) in D₂O and in CD₃OD are shown in Fig. 9. Furthermore, COSY spectra of $[(\eta^6-p-cym)Ru(mecys)]Cl(1)$ in D₂O, $[(\eta^6-p-cym)Ru(mecys)]Cl(1)$ in D₂O, cym)Ru(mecys)]CF₃SO₃ (12) in CD₃OD (Fig. S5) and HSQC spectrum of $[(\eta^6-p$ cym)Ru(mecys)]Cl (1) in D₂O (Fig S6.) are also presented. In all cases (Fig. 9) the very similar doubling of the resonances of the ring hydrogens (5.7–6.3 ppm) and those of the ¹Prmethyl protons (1.20–1.35 ppm) of the *p*-cymene ligand supports the loss of symmetry of the arene because the metal ion also becomes a chirality centre upon coordination of the mecys ligand. COSY (Fig. S5b) and HSQC (Fig. S6) also indicate that the methylene hydrogens of the ligand exhibit rather different δ values (2.80 (dd) and 2.40 (d) ppm) due to their nonequivalent environment in the complex. Regarding the ring protons of *p*-cymene, for example in Fig. 9b, the signals at 5.86 and 5.91 ppm belong to a strongly coupled AB spin system while those at 5.74 and 6.07 ppm to a weakly coupled MX system.

Careful analysis of the NMR spectra (Fig. 9, S5 and S6) also reveals that beside the major complex, resonances of a minor species are also present. COSY spectrum (Fig. S5) indicates that there is no cross-coupling between the signals of the major and minor species, furthermore, analytical information also supports the presence of complexes with identical (i.e. 1:1 metal ion to ligand) stoichiometry only.

With the interaction of L-mecys and $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ a "chiral-at-metal" complex is formed and owing to the tridentate coordination of the chiral ligand, the configuration of the metal ion is determined resulting in the exclusive formation of the $R_{Ru}R_{\alpha C}$ stereoisomer.

When coordinating, the thioether-S also becomes a stereogenic centre in the complex. Unlike the metal ion and αC , the thioether-S has labile configuration in the complexes²⁴ which can rationalize the NMR results. It is very likely that the major resonances in the spectra belong to the thermodynamically preferred $R_{Ru}R_{\alpha C}S_S$ diastereomer (also supported by the X-ray structure) while the minor ones to $R_{Ru}R_{\alpha C}R_{S}$, formed after dissolution of the solid. With this assumption all the resonances in the spectra (Fig. 9, S5 and S6) can be assigned (Table 5). As Fig S5 and S6 reveal, the largest chemical shift differences for the S-methyl (**D**) and β -CH₂ (B) protons as well as carbon atoms can be observed in accordance with the structural differences of the two epimers (Fig. S7). For all the $[(\eta^6-p-cym)Ru(mecys)]X$ (X = Cl, NO₃, CF₃SO₃), $[(\eta^6-p-cym)Os(mecys)]Cl$ or $[(\eta^5-Cp^*)M'(mecys)]Cl$ complexes the calculated amount of the minor diastereomer (%) together with the diastereomeric excess (de %) are summarized in Table 6. As it is seen in Table 6 the solvent has slightly larger influence on the ratio than the counter ion. Comparing the metals, for the Os complexes the epimerization is the most pronounced. For the Rh complex broadening of the signals was observed at ambient temperature, however, for the cooled samples the minor isomer could also be detected (see Fig. S8). The ratios of the diastereomers (Table 6) did not change either in a longer period of time (days) or by increasing the temperature of the samples; in the latter case faster exchange processes were only observed.

For the DL-met containing complexes broadening of the signals in the ¹H NMR and COSY spectra (Fig. 10a and S9a) at room temperature was detected. This is because of the frequency difference between the resonances is comparable to the frequency of the interconversion of the epimers. To support this, as it is seen in Fig. 10, S9 and S10, on cooling the samples the resonances become sharper owing to slower processes. Analysis of the spectra (see Fig. 10c as a representative example) reveals identical situation for the met containing complexes as it was found for the mecys compounds previously: beside a major species a minor one is also present in solution in every system. Again, for both complexes tridentate binding mode of the ligand with the difference in the configuration of the coordinating thioether S can be assumed. Interestingly, for the met complex, due to the chirality of the sulfur atom, the γ -C protons also become magnetically non-equivalent. The chemical shift difference is larger for these protons than that of the β -C protons (Fig. S10) supporting the epimerization of sulfur atoms as it was detected in the mecys system. Significant broadening at room temperature in the case of the met complexes over the mecys ones can be rationalized by the formation of the more flexible

six-membered (S,N) and five-membered (N,O) joined chelate rings with the former ligand over the more rigid 5+5 membered chelates present in the mecys complexes.

It is worth emphasizing that with the racemic DL-met four stereoisomers can be formed. Tridentate coordination of L-met (with S absolute configuration) or D-met (with R absolute configuration) again will determine the configuration of the metal ion as stereogenic centre in the "chiral-at-metal" complexes resulting in $R_{Ru}S_{\alpha C}$ or $S_{Ru}R_{\alpha C}$ stereoisomers. Furthermore, with the coordination of the thioether S the following isomers can be expected: $R_{Ru}S_{\alpha C}R_S(1)$ and $R_{Ru}S_{\alpha C}S_S(2)$ for the L- and $S_{Ru}R_{\alpha C}S_S(3)$ and $S_{Ru}R_{\alpha C}R_S(4)$ for D-met. Although 1 can be distinguished both from 2 and 4 by its different resonances in the NMR spectrum, since 2 and 4 form enantiomers, only two sets of NMR resonances are expected. To confirm this NMR spectrum of $[(\eta^6-p-cym)Ru(L-met)]Cl$ (3) was also registered and found to be identical with that of the DL-met containing spectrum.

The calculated ratio of the diastereomers (%) for all the $[(\eta^6-p\text{-}cym)Ru(DL\text{-}met)]NO_3 [(\eta^6-p\text{-}cym)Os(DL\text{-}met)]Cl or <math>[(\eta^5\text{-}Cp^*)M'(DL\text{-}met)]Cl$ complexes together with the diastereomeric excess (de %) are summarized in Table 6. As it is seen in Table 6 cooling did not alter significantly the ratios, furthermore, with met the amount of the minor epimer is larger than previously found with mecys (Table 6). This can be explained with the presence of the more flexible jointed six-membered (S,N) and five-membered (N,O) chelates in the case of the met complexes over the mecys ones. Similarly as for mecys, in the case of $[(\eta^5\text{-}Cp^*)Rh(DL\text{-}met)]Cl$ (7) the minor diastereomer can only be detected at lower temperature (Fig. S11).

Cytotoxicity in cancer cells.

The *in vitro* anti-cancer chemotherapeutic potential of the complexes **3**, **7**, **9** and **11** towards a human ovarian cancer cell line (A2780) was also tested. Several assays are commonly used for *in vitro* chemosensitivity testing of tumour cell lines, although use of them has various advantages and limitations. It is so because the principles of these assays are differently dependent on metabolic and other factors and/or some compounds can directly interfere with reactions responsible for conversion of the colourless dye to the coloured product without having any effects on cell viability which may, in turn, substantially affect the quantitation of cell viability. Therefore two independent assays, MTT and NR assays have been employed to determine cytotoxic effect of the compound tested in this work. The MTT assay requires cellular metabolic activity (measures mitochondria dehydrogenase activity as a marker of cell

viability) to convert the colourless tetrazolium to the purple-coloured formazan dye. On the other hand, the neutral red uptake assay is based on the ability of viable cells to incorporate and bind the dye in lysosomes by an active metabolic process.

The results clearly showed that all complexes (3, 7, 9 and 11) tested in this work have insignificant anti-proliferative properties, since they failed to reduce the viability of the model cell line across both the concentration range (0–50 μ M) and incubation period (72 h) studied. In contrast, cisplatin displayed a significant reduction in cellular viability of A2780 cells under the same conditions with mean IC₅₀ values of 3.4 ± 0.3 μ M and 2.8 ± 0.1 μ M determined by MTT and NR assay, respectively. The IC₅₀ > 50 μ M values obtained for 3, 7, 9 and 11 are in contrast with recently published results²⁰ but might be rationalized by the different experimental conditions applied.

Conclusions

In summary, we have demonstrated that the amino acids, S-methyl-L-cysteine and DLmethionine, both bearing a thioether S donor too, are efficient binders for half-sandwich type platinum metal ions over a wide pH-range in aqueous solution. Combined pH-potentiometry, NMR and MS as well as single crystal X-ray diffraction methods indicated the ligands to coordinate via a [S, NH₂, COO⁻] manner in the complexes. The slightly higher stability of $[(\eta^6-p-cym)Ru(met)]^+$ over the mecys analogue was rationalized by the more flexible (6+5) membered joined chelates with the former ligand compared to the (5+5) membered ones formed with mecys. Solution behaviour of the solid complexes after redissolving them in various solvents showed that with both ligands beside the major stereoisomer a minor one with the different configuration of the coordinating thioether S only is also formed. The extent of epimerization was found to be higher for the met containing complexes due to the less rigid chelate ring formed. This kinetically labile character of the thioether S donor atom may have a significant contribution to the experimental findings, namely, the studied complexes, although they are characterized by high thermodynamic stability, do not show in vitro antiproliferative activity against A2780 human derived cancer cell lines in the concentration range 0-50 µM most likely due to their insufficient kinetic inertness.

Supporting Information (see footnote of the first page of this article): titration curves with S-methyl-L-cysteine for the H⁺-ligand system and the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -ligand

RSC Advances Accepted Manuscript

systems at 1:2, 1:1 and 2:1 ratios; dependence on pH of the ¹H NMR spectra of the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -met system at 1:1 ratio and at 298 K in D₂O; hypothetical concentration distribution curves of the $[(\eta^6-p-cym)Ru]^{2+}$ -met-citr-ise system at 1:1:1:1 ratio; superimposed molecular structures of the two conformers of the $R_{Ru}R_{\alpha C}S_S$ diastereomer of $[(\eta^6-p-cym)Ru(mecys)]NO_3$ (**10**); COSY spectra of $[(\eta^6-p-cym)Ru(mecys)]Cl$ (**1**) in D₂O, $[(\eta^6-p-cym)Ru(mecys)]CF_3SO_3$ (**12**) in CD₃OD and $[(\eta^6-p-cym)Ru(met)]NO_3$ (**11**) in D₂O at 298K as well as $[(\eta^6-p-cym)Ru(met)]NO_3$ (**11**) in D₂O at 273K; Newmann projection of the two diastrereomers of $[(\eta^6-p-cym)Ru(met)]^+$; HSQC spectra of $[(\eta^6-p-cym)Ru(mecys)]Cl$ (**1**) in D₂O at 298K and $[(\eta^6-p-cym)Ru(met)]NO_3$ (**11**) in D₂O at 273K; dependence on temperature of the ¹H NMR spectra of $[(\eta^5-Cp^*)Rh(mecys)]Cl$ (**6**) and $[(\eta^5-Cp^*)Rh(met)]Cl$ (**7**) in D₂O at 298, 283 and 273 K.

Acknowledgements:


The authors thank members of the EU COST CM1105 for motivating discussions. The research was supported by EU and co-financed by the European Social Fund under the project ENVIKUT (TAMOP-4.2.2.A-11/1/KONV-2012-0043) and by the Hungarian Scientific Research Fund (OTKA K112317).

References

- 1 M. Melchart, P. J. Sadler, in *Bioorganometallics*, ed. G. Jaouen, Wiley-VCH, Weinheim, Germany, 2006, p. 39-64.
- 2 P. C. A. Bruijnincx, P. J. Sadler, Adv. Inorg. Chem., 2009, 61, 1-62.
- 3 I. Bratsos, T. Gianferrara, E. Alessio, C. G. Hartinger, M. A. Jakupec, B. K. Keppler, in *Bioinorganic Medicinal Chemistry*, ed. E. Alessio, Wiley-VCH, Weinheim, Germany, 2011, p. 160-164.
- 4 G. Süss-Fink, *Dalton Trans.*, 2010, **39**, 1673-1688.
- 5 G. Süss-Fink, J. Organomet. Chem, 2014, 751, 2-19.
- 6 L. Bíró, E. Farkas, P. Buglyó, *Dalton Trans.*, 2010, **39**, 10272-10278.
- 7 L. Bíró, D. Hüse, A. C. Bényei, P. Buglyó, J. Inorg. Biochem., 2012, 116, 116-125.
- 8 D. Hüse, L. Bíró, J. Patalenszki, A. C. Bényei, P. Buglyó, *Eur. J. Inorg. Chem.*, 2014, 5204-5216.
- 9 L. Bíró, E. Balogh, P. Buglyó, J. Organomet. Chem., 2013, 734, 61-68.
- 10 K. Severin, R. Bergs, W. Beck, Angew, Chem. Int. Ed., 1998, 37, 1634-1654.

- 11 F. Wang, H. Chen, J. A. Parkinson, P. Murdoch, P. J. Sadler, *Inorg. Chem.*, 2002, **41**, 4509-4523.
- 12 L. E. H. Paul, B. Therien, J. Furrer, J. Biol. Inorg. Chem., 2012, 17, 1053-1062.
- 13 W. S. Sheldrick, S. Heeb, J. Organomet. Chem., 1989, 377, 357-366.
- 14 G. Capper, D. L. Davies, J. Fawcett, D. R. Russel, Acta Crystallogr., Sect. C: Struct. Chem., 1995, **51**, 578-580.
- 15 W. S. Sheldrick, R. Exner, J. Organomet. Chem., 1990, 386, 375-387.
- 16 W. S. Sheldrick, A. Gleichmann, J. Organomet. Chem., 1994, 470, 183-187.
- 17 M. Scharwitz, T. van Almsick, W. S. Sheldrick, *Acta Crystallogr., Sect. E: Struct. Rep.* Online., 2007, **63**, 230-232.
- 18 X. L. Lu, L. Zhang, J.-D. Lou, J. Yan, P.-S. Nong, X.-H. Chen, J.-J. Yang, M. Gao, *Transition Met. Chem.*, 2010, 35, 513-519.
- 19 A. Buryak, K. Severin, Angew. Chem. Int. Ed., 2004, 43, 4771-4774.
- 20 F. A. Egbewande, L. E. H. Paul, B. Therrien, J. Furrer, *Eur. J. Inorg. Chem.*, 2014, 1174-1184.
- 21 D. Carmona, M. P. Lamata, F. Viguri, E. San José, A. Mandoza, F. J. Lahoz, P. García-Orduña, R. Atencio, L. A. Oro, J. Organomet. Chem., 2012, 717, 152-163.
- 22 C. Ganter, Chem. Soc. Rev., 2003, 32, 130-138.
- 23 H. Brunner, Eur. J. Inorg. Chem., 2001, 905-912.
- 24 I. Weber, F. W. Heinemann, W. Bauer, U. Zenneck, Z. Naturforsch., B: J. Chem. Sci., 2009, 64, 123–140.
- 25 D. D. Perrin, W. L. F. Armarego, *Purification of Laboratory Chemicals*, 3rd ed., Pergamon, Oxford, UK, 1988.
- 26 M. A. Bennett, A. K. Smith, J. Chem. Soc., Dalton Trans., 1974, 233-241.
- 27 A. J. Godó, A. C. Bényei, B. Duff, D. A. Egan, P. Buglyó, RSC Adv., 2012, 2, 1486– 1495.
- 28 A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, J. Appl. Crystallogr. 1993, 26, 343–350.
- 29 G. M. Sheldrick, Acta Crystallogr., Sect. A: Found. Adv., 2008, 64, 112–122.
- 30 L. J. Farrugia, J. Appl. Crystallogr., 1999, 32, 837-838.
- 31 G. Gran, Acta Chem. Scand., 1950, 4, 559–577.
- 32 H. M. Irving, M. G. Miles, L. D. Pettit, Anal. Chim. Acta, 1967, 38, 475–488.
- 33 A. Krężel, W. Bal, J. Inorg. Biochem., 2004, 98, 161-166.

- 34 L. Zékány, I. Nagypál, in: *Computational Methods for the Determination of Stability Constants*, ed. D. Leggett, Plenum, New York, 1985, p. 291–299.
- 35 P. Gans, A. Sabatini, A. Vacca, J. Chem. Soc., Dalton Trans., 1985, 1195–1200.
- 36 L. Bíró, E. Farkas, P. Buglyó, Dalton Trans., 2012, 41, 285-291.
- 37 V. Novohradsky, L. Zerzankova, J. Stepankova, A. Kisova, H. Kostrhunova, Z. Liu, P. J.
 Sadler, J. Kasparkova, V. Brabec, *Metallomics*, 2014, 6, 1491-1501.
- 38 I. Sóvágó, K. Várnagy, A. C. Bényei, Magy. Kém. Foly., 1986, 92, 114-116.
- 39 W. S. Sheldrick, E. Hauck, S. Korn, J. Organomet. Chem., 1994, 467, 283-292.



25

Compound	10	11
Formula	$C_{14}H_{22}NO_2RuS\cdot NO_3$	$C_{15}H_{24}NO_2RuS\cdot NO_3$
Formula weight	431.46	445.49
Crystal system	Monoclinic	Monoclinic
Space group (No.)	P2 ₁ (4)	P2 ₁ /n (14)
<i>a</i> / Å	12.891(1)	12.591(1)
<i>b</i> / Å	7.611(1)	7.029(1)
<i>c</i> / Å	18.041(1)	19.817(1)
lpha / °	90.00	90.00
β / °	99.51(1)	105.50(1)
γ/°	90.00	90.00
$V/\text{\AA}^3$	1745.7(3)	1690.1(5)
Ζ	4	4
$D_{\rm c}$ / g cm ⁻³	1.642	1.751
F(000)	880	912
μ/mm^{-1}	1.04	1.08
Reflections collected	4194	3527
Unique reflections	3395	3317
Reflections with $I > 2\sigma(I)$	1992	2696
Parameters refined	418	221
$\operatorname{GOF}^{\mathrm{a}}$ on F^2	1.04	1.25
$R^{\rm b} [F^2 > 2\sigma(F^2)]$	0.074	0.078
R _{int}	0.072	0.041
$wR(F^2)^{\rm b}$	0.168	0.204
$\Delta \rho_{\rm max}, \Delta \rho_{\rm min}$ / e Å ⁻³	0.96, -1.02	1.62, -2.28

Table 1. Crystallographic data and structure refinement results for $[(\eta^6-p-cym)Ru(mecys)]NO_3$ (**10**) and $[(\eta^6-p-cym)Ru(DL-met)]NO_3$ (**11**).

^a GOF = $[\Sigma\omega(F_o^2 - F_o^2)^2/(n-p)]^{1/2}$ ^b $R_1 = \Sigma ||F_o| - |F_c||/\Sigma|F_o|, \ \omega R_2 = [\Sigma\omega(F_o^2 - F_o^2)^2/\Sigma\omega F_o^2]^{1/2}$

Table 2. Stepwise protonation constants (log*K*) of the ligands and stability constants (log β) of the [(η^6 -*p*-cym)Ru]²⁺ complexes at 25.0 ^o C and I = 0.20 M (KNO₃).^a

	mecys	met
logK _{HA}	8.76(1)	9.04(1)
logK _{H2A}	2.01(1)	2.16(1)
$\log \beta_{[RuA]^+}$	$16.4(4)^{b}$	$17.2(2)^{b}$

^a 3σ standard deviations are in parentheses; "Ru" stands for the $[(\eta^6-p-cym)Ru]^{2+}$ entity.

^b Estimated from ¹H NMR data.

Ligan d	рН	Specie s	δ(S- CH ₃) D	δ(β- CH ₂) B	δ(β- CH ₂) B'	δ(γ- CH ₂) C	δ(α-CH) A	² J _{BB}	³ J _{AB}	³ J _A B'	${}^{3}J_{BC}$ = ${}^{3}J_{B'C}$
	0.83				3.20 (dd)						_
mecys	11.96	[A] ⁻	2.11 (s)	2.74 (dd)	2.83 (dd)	_	3.42 (dd)	13. 6	6.9	5.2	_
	1.02	$\left[\mathrm{H}_{2}\mathrm{A}\right]^{+}$	2.12 (s)	2.20 (m)	2.31 (m)	2.70 (t)	4.25 (dd)	_b	6.6	6.2	7.3
met	12.21	[A] ⁻	2.11 (s)	1.80 (m)	1.91 (m)	2.55 (t)	3.32 (dd)	_ ^b	7.2	5.6	7.8

Table 3. Chemical shifts (ppm) and spin-spin coupling constants (Hz) of the ligand hydrogens in $D_2Otogether$ with the multiplicities in parentheses.^a

^a Labelling of the hydrogens is shown in Scheme 1.

^b Cannot be determined due to the multiplicity of these resonances.

Table 4. Selected bond lengths (Å) and angles (°) for complexes $[(\eta^6-p-cym)Ru(mecys)]NO_3$ (10) and $[(\eta^6-p-cym)Ru(DL-met)]NO_3$ (11).

	10	11		10	11
S(1)-Ru(1)	2.407(6)	2.390(2)	O(1)-Ru(1)-S(1)	85.5(4)	86.38(18)
N(1)- $Ru(1)$	2.140(19)	2.113(7)	N(1)-Ru(1)-S(1)	79.5(5)	88.7(2)
O(1)-Ru(1)	2.079(12)	2.095(6)	O(1)-Ru(1)-N(1)	76.4(6)	76.7(2)
Ru(1)-C _{cymene center}	1.667	1.660	C(4)-S(1)-Ru(1)	108.3(9)	—
C(1)-O(1)	1.21(2)	1.233(10)	C(5)-S(1)-Ru(1)	_	107.6(4)
C(1)-O(2)	1.27(2)	1.280(10)	O(51)-Ru(2)-S(2)	86.2(4)	—
S(2)-Ru(2)	2.396(6)	_	N(51)-Ru(2)-S(2)	80.2(5)	—
N(51)-Ru(2)	2.100(18)	—	N(51)-Ru(2)-O(51)	76.2(6)	—
O(51)-Ru(2)	2.112(13)	—	C(54)-S(2)-Ru(2)	106.3(9)	—
Ru(2)-C _{cymene center}	1.685	_			
C(51)-O(51)	1.31(3)	_			
C(51)-O(52)	1.27(2)	_			

RSC Advances Accepted Manuscript

•							
Complex		(1)	(12)	(4	4)	(6) ^b	(8)
Solvent		D_2O	CD ₃ OD	D_2O	CD ₃ OD	D_2O	D_2O
D (s)	major	2.39	2.43	2.43	2.48	2.38	2.42
$\mathbf{D}(\mathbf{s})$	minor	2.85	2.86	2.93	2.98	2.72	2.79
D (4)	major	2.40	2.40	2.39	2.40	2.65	2.67
B (d)	minor	3.03	2.99	2.97	2.91	3.28	3.25
B' (dd)	major	2.80	2.74	2.87	2.85	2.99	3.03
D (uu)	minor	overlap	overlap	2.53	2.56	overlap	overla
A (d)	major	3.84	3.72	4.05	3.92	3.96	4.31
A (u)	minor	3.76	3.64	3.90	3.78	3.86	4.11
		1.27	1.30	1.25	1.30		
E/E' (d)	major	1.29	1.33	1.27	1.32		
	minor	1.32	1.36	1.29	1.33		
I (s)	major	2.22	2.22	2.29	2.31		
	minor	2.27	2.27	2.35	2.38		
E (b)	major	2.79	2.79	2.70	2.71		
F (h)	minor	overlap	overlap	overlap	overlap		
	major	5.74	5.74	5.94	5.93		
		5.89	5.86	6.05	6.02		
		5.92	5.91	6.13	6.13		
G/G'/H/H' (d)		6.08	6.07	6.27	6.25		
		5.43	5.37	5.66	5.62		
		overlap	5.95	overlap	6.29		
	minor	overlap	6.12	overlap	overlap		
		overlap	overlap	overlap	overlap		
T ()	major					1.83	1.85
J (s)	minor					1.76	1.83

Table 5. Chemical shift values (δ ; ppm) of the protons of the complexed mecys and the pentaor hexahapto bound aromatic ligands of the metal ion in the complexes together with the multiplicity of these resonances in parentheses.^a

^a Notation of the A–J protons can be seen in Scheme 1. ^b Determined at 0 °C.

Complex	minor isomer%	de%
$[(\eta^6-p-\text{cym})\text{Ru}(\text{mecys})]\text{Cl}(1)$	12.7	74.6
$[(\eta^6-p-\text{cym})\text{Ru}(\text{mecys})]\text{NO}_3$ (10)	10.9	78.2
$[(n^{6} n \text{ avm})\mathbf{P}u(maava)]\mathbf{CE} \mathbf{SO} (12)$	11.5	77.0
$[(\eta^{\circ}-p-\text{cym})\text{Ru}(\text{mecys})]\text{CF}_3\text{SO}_3 (12)$	14.3 ^a	71.4
$[(\eta^6-p-\text{cym})Os(\text{mecys})]Cl(4)$	13.7	72.6
	15.9 ^a	68.2
$[(\eta^5-Cp^*)Rh(mecys)]Cl(6)$	4.6 ^b	90.8
$[(\eta^5-Cp^*)Ir(mecys)]Cl(8)$	5.4	89.2
$\left[\left(\frac{1}{2}\right)^{6}\right]$	25.6	48.8
$[(\eta^{6}-p-\text{cym})\text{Ru}(\text{DL-met})]\text{NO}_{3} (11)$	25.1 ^b	49.8
$\overline{[(\eta^6-p-cym)Os(DL-met)]Cl(5)}$	26.0 ^b	48.0
$\overline{[(\eta^5-Cp^*)Rh(DL-met)]Cl(7)}$	32.0 ^b	36.0
	41.0	18.1
$[(\eta^{5}-Cp^{*})Ir(DL-met)]Cl (9)$	38.1 ^b	23.8

Table 6. Percentage amount of the minor isomer with the percentage of the diastereomer excess estimated from the NMR spectra in D_2O and at 25 °C.

^a in CD₃OD

^b at 0 °C.




Figure 1. Titration curves with DL-methionine for the H⁺–ligand system (a) and the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ –ligand systems at 1:2 (b), 1:1 (c) and 2:1 (d) ratios. Negative base equivalent refers to an excess of acid in the sample.




Figure 2. Dependence on pH of the ¹H NMR spectra of the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -mecys system at 1:1 ratio and at 298 K in D₂O (I = 0.20 M KNO₃, c_{Ru} = 10.0 mM). "Ru" stands for the $[(\eta^6-p-cym)Ru]^{2+}$ entity.




Figure 3. Dependence on pH of the ¹H NMR spectra of $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -met system at 1:1 ratio and at 298 K in H₂O (I = 0.20 M KNO₃, c_{Ru} = 13.0 mM). "Ru" stands for the $[(\eta^6-p-cym)Ru]^{2+}$ entity.




Figure 4. Calculated concentration distribution curves for the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -met system at 1:1 ratio. $c_{Ru} = 13$ mM. Inlet shows the calculated curves together with the percentage of the species estimated by the ratio of the area of the NMR signals belonging to $[RuA]^+$ (\blacksquare) and $[(\eta^6-p-cym)Ru(\mu^2-OH)_3]^+$ (\circ). "Ru" refers to $[(\eta^6-p-cym)Ru]^{2+}$.




Figure 5. Dependence on pH of the ¹H NMR spectra of the $[(\eta^6-p-cym)Ru(H_2O)_3]^{2+}$ -mecysmet system at 1:1:1 ratio, at 298 K in D₂O, with any form of the uncomplexed mecys (a) or met (b). (I = 0.20 M KNO₃, c_{Ru} = 20.0 mM). "Ru" refers to $[(\eta^6-p-cym)Ru]^{2+}$.




Figure 6. ESI-MS spectrum of an aqueous 1:1 $[(\eta^6-p-cym)Ru]^{2+}$ -met sample at pH = 10.8, c_{Ru} = 0.3 mM. Inlet shows representative observed and expected ESI-MS spectra of $[(\eta^6-p-cym)Ru(met)]^+$. "Ru" refers to $[(\eta^6-p-cym)Ru]^{2+}$.




Figure 7. Molecular structure of the $R_{Ru}R_{\alpha C}S_S$ diastereomer of the $[(\eta^6-p-cym)Ru(mecys)]NO_3$ (10) complex exhibiting two slightly different conformers.




Figure 8. Molecular structure of the $S_{Ru}R_{\alpha C}S_{S}$ diastereomer of the $[(\eta^{6}-p-cym)Ru(DL-met)]NO_{3}$ (11) complex (the $R_{Ru}S_{\alpha C}R_{S}$ enantiomer is not shown).




Figure 9. NMR spectra of $[(\eta^6-p-cym)Ru(mecys)]NO_3$ (10) in D₂O (a), $[(\eta^6-p-cym)Ru(mecys)]CF_3SO_3$ (12) in CD₃OD (b), $[(\eta^6-p-cym)Os(mecys)]Cl$ (4) in D₂O (c) and in CD₃OD (d) together with the notation of the hydrogens according to Scheme 1. Resonances of the major diastereomer are marked with \circ , while those of the minor one with \blacktriangle .




Figure 10. ¹H NMR spectra of $[(\eta^6-p-cym)Ru(mecys)]NO_3$ (11) in D₂O at 298 K (a), 283 K (b) and 273 K (c). Triplets at 1.17 ppm and quartets at 3.65 ppm originate from ethanol while the triplets at 2.91 ppm from TSP. Notation of the A-I protons can be seen in Scheme 1. Resonances of the major diastereomer are marked with \circ , while those of the minor one with \blacktriangle .